Wqqq_老虎社区_美港股上老虎

rachellll
2022-01-13

Wqqq

Salarius Plans To Enter $15B Protein Degradation Space With DeuteRx Deal<blockquote>Salarius计划通过DeuteRx交易进入价值15B美元的蛋白质降解领域</blockquote>

Salarius Pharmaceuticals Inc has agreed to acquire an oral, small molecule targeted protein degradat

Salarius Plans To Enter $15B Protein Degradation Space With DeuteRx Deal<blockquote>Salarius计划通过DeuteRx交易进入价值15B美元的蛋白质降解领域</blockquote>

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":694421209,"tweetId":"694421209","gmtCreate":1642084162295,"gmtModify":1642084163402,"author":{"id":3586435391928672,"idStr":"3586435391928672","authorId":3586435391928672,"authorIdStr":"3586435391928672","name":"rachellll","avatar":"https://static.tigerbbs.com/7855a29f75174783f11b5102e8a7c8ba","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":29,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Wqqq</p></body></html>","htmlText":"<html><head></head><body><p>Wqqq</p></body></html>","text":"Wqqq","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/694421209","repostId":1128321741,"repostType":4,"repost":{"id":"1128321741","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1642082676,"share":"https://www.laohu8.com/m/news/1128321741?lang=zh_CN&edition=full","pubTime":"2022-01-13 22:04","market":"us","language":"en","title":"Salarius Plans To Enter $15B Protein Degradation Space With DeuteRx Deal<blockquote>Salarius计划通过DeuteRx交易进入价值15B美元的蛋白质降解领域</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1128321741","media":"Benzinga","summary":"Salarius Pharmaceuticals Inc has agreed to acquire an oral, small molecule targeted protein degradat","content":"<p><html><head></head><body><b>Salarius Pharmaceuticals Inc</b> has agreed to acquire an oral, small molecule targeted protein degradation portfolio against cancer from <b>DeuteRx LLC</b>.</p><p><blockquote><html><head></head><body><b>Salarius制药公司</b>已同意从以下公司收购针对癌症的口服小分子靶向蛋白质降解产品组合<b>DeuteRx有限责任公司</b>.</body></html></blockquote></p><p><ul><li>The acquisition includes a lead drug candidate that Salarius has renamed SP-3164 (formerly DRX-164).</li><li>&#34;This strategic acquisition is a transformative event for Salarius that significantly expands our development pipeline while building upon the momentum of our lead clinical-stage candidate, seclidemstat,&#34; stated David Arthur, CEO of Salarius.</li><li>SP-3164 is a next-generation cereblon-binding molecular glue. Molecular glues are small molecules that commandeer the body&#39;s normal protein-degradation processes and induce selective elimination of cancer-causing proteins.</li><li>Salarius plans to begin the first clinical trial in 2023.</li><li>As part of the agreement, Salarius and DeuteRx will collaborate to complete SP-3164 development activities and collaborate on the R&amp;D of future products.</li><li>Under the agreement terms, DeuteRx will receive an upfront payment consisting of $1.5 million in cash and 1 million shares of restricted stock.</li><li>SP-3164, DeuteRx is also entitled to receive up to $188 in milestone payments.</li><li>Additionally, DeuteRx is eligible to receive milestone payments of up to $84 million for each of two future products.</li><li><b>Price Action:</b> SLRX shares traded 1.52% higher at $0.50 premarket on the last check Thursday.</li></ul></body></html></p><p><blockquote><ul><li>此次收购包括Salarius已将其更名为SP-3164（原DRX-164）的主要候选药物。</li><li>Salarius首席执行官David Arthur表示：“此次战略收购对Salarius来说是一次变革性事件，它显着扩大了我们的开发渠道，同时巩固了我们领先的临床阶段候选药物seclidemstat的势头。”</li><li>SP-3164是下一代小脑蛋白结合分子胶。分子胶是控制身体正常蛋白质降解过程并诱导选择性消除致癌蛋白质的小分子。</li><li>Salarius计划于2023年开始首次临床试验。</li><li>作为协议的一部分，Salarius和DeuteRx将合作完成SP-3164的开发活动，并就未来产品的研发进行合作。</li><li>根据协议条款，DeuteRx将获得包括150万美元现金和100万股限制性股票在内的预付款。</li><li>SP-3164，DeuteRx还有权获得高达188美元的里程碑付款。</li><li>此外，DeuteRx还有资格为未来两款产品中的每款获得高达8400万美元的里程碑付款。</li><li><b>价格走势：</b>周四最后一次盘前检查时，SLRX股价上涨1.52%，至0.50美元。</li></ul></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Salarius Plans To Enter $15B Protein Degradation Space With DeuteRx Deal<blockquote>Salarius计划通过DeuteRx交易进入价值15B美元的蛋白质降解领域</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSalarius Plans To Enter $15B Protein Degradation Space With DeuteRx Deal<blockquote>Salarius计划通过DeuteRx交易进入价值15B美元的蛋白质降解领域</blockquote>\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time smaller\">2022-01-13 22:04</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<p><html><head></head><body><b>Salarius Pharmaceuticals Inc</b> has agreed to acquire an oral, small molecule targeted protein degradation portfolio against cancer from <b>DeuteRx LLC</b>.</p><p><blockquote><html><head></head><body><b>Salarius制药公司</b>已同意从以下公司收购针对癌症的口服小分子靶向蛋白质降解产品组合<b>DeuteRx有限责任公司</b>.</body></html></blockquote></p><p><ul><li>The acquisition includes a lead drug candidate that Salarius has renamed SP-3164 (formerly DRX-164).</li><li>&#34;This strategic acquisition is a transformative event for Salarius that significantly expands our development pipeline while building upon the momentum of our lead clinical-stage candidate, seclidemstat,&#34; stated David Arthur, CEO of Salarius.</li><li>SP-3164 is a next-generation cereblon-binding molecular glue. Molecular glues are small molecules that commandeer the body&#39;s normal protein-degradation processes and induce selective elimination of cancer-causing proteins.</li><li>Salarius plans to begin the first clinical trial in 2023.</li><li>As part of the agreement, Salarius and DeuteRx will collaborate to complete SP-3164 development activities and collaborate on the R&amp;D of future products.</li><li>Under the agreement terms, DeuteRx will receive an upfront payment consisting of $1.5 million in cash and 1 million shares of restricted stock.</li><li>SP-3164, DeuteRx is also entitled to receive up to $188 in milestone payments.</li><li>Additionally, DeuteRx is eligible to receive milestone payments of up to $84 million for each of two future products.</li><li><b>Price Action:</b> SLRX shares traded 1.52% higher at $0.50 premarket on the last check Thursday.</li></ul></body></html></p><p><blockquote><ul><li>此次收购包括Salarius已将其更名为SP-3164（原DRX-164）的主要候选药物。</li><li>Salarius首席执行官David Arthur表示：“此次战略收购对Salarius来说是一次变革性事件，它显着扩大了我们的开发渠道，同时巩固了我们领先的临床阶段候选药物seclidemstat的势头。”</li><li>SP-3164是下一代小脑蛋白结合分子胶。分子胶是控制身体正常蛋白质降解过程并诱导选择性消除致癌蛋白质的小分子。</li><li>Salarius计划于2023年开始首次临床试验。</li><li>作为协议的一部分，Salarius和DeuteRx将合作完成SP-3164的开发活动，并就未来产品的研发进行合作。</li><li>根据协议条款，DeuteRx将获得包括150万美元现金和100万股限制性股票在内的预付款。</li><li>SP-3164，DeuteRx还有权获得高达188美元的里程碑付款。</li><li>此外，DeuteRx还有资格为未来两款产品中的每款获得高达8400万美元的里程碑付款。</li><li><b>价格走势：</b>周四最后一次盘前检查时，SLRX股价上涨1.52%，至0.50美元。</li></ul></blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SLRX":"Salarius Pharmaceuticals Inc"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1128321741","content_text":"Salarius Pharmaceuticals Inc has agreed to acquire an oral, small molecule targeted protein degradation portfolio against cancer from DeuteRx LLC.The acquisition includes a lead drug candidate that Salarius has renamed SP-3164 (formerly DRX-164).\"This strategic acquisition is a transformative event for Salarius that significantly expands our development pipeline while building upon the momentum of our lead clinical-stage candidate, seclidemstat,\" stated David Arthur, CEO of Salarius.SP-3164 is a next-generation cereblon-binding molecular glue. Molecular glues are small molecules that commandeer the body's normal protein-degradation processes and induce selective elimination of cancer-causing proteins.Salarius plans to begin the first clinical trial in 2023.As part of the agreement, Salarius and DeuteRx will collaborate to complete SP-3164 development activities and collaborate on the R&D of future products.Under the agreement terms, DeuteRx will receive an upfront payment consisting of $1.5 million in cash and 1 million shares of restricted stock.SP-3164, DeuteRx is also entitled to receive up to $188 in milestone payments.Additionally, DeuteRx is eligible to receive milestone payments of up to $84 million for each of two future products.Price Action: SLRX shares traded 1.52% higher at $0.50 premarket on the last check Thursday.","news_type":1,"symbols_score_info":{"SLRX":0.9}},"isVote":1,"tweetType":1,"viewCount":1811,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":4,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}

Salarius Plans To Enter $15B Protein Degradation Space With DeuteRx Deal<blockquote>Salarius计划通过DeuteRx交易进入价值15B美元的蛋白质降解领域</blockquote>

评论（1）

热议股票